.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Neurogenic detrusor overactivity can cause urgency and urinary incontinence in multiple sclerosis and spinal cord injury despite oral antimuscarinic therapy. In this prospective double-blind multicentre trial, patients with persistent urinary incontinence were randomized to intradetrusor onabotulinumtoxinA or placebo. Active treatment reduced the frequency of daily urinary incontinence and improved validated quality-of-life measures during the primary follow-up period. The study provides strong evidence for botulinum toxin as a local therapy when oral medication does not adequately control neurogenic bladder symptoms. The clinical trade-off is the risk of urinary retention, which may necessitate intermittent catheterisation. For HCPs, the practical pathway is therefore to assess bladder-emptying function before treatment and counsel patients about catheterisation if necessary. The intervention should form part of a broader neuro-urological assessment rather than being used solely to suppress urgency. The findings are directly relevant to IANCON's neuro-urology workshop, which addresses assessment and management of neurogenic bladder and sexual dysfunction in neurological patients.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Neurogenic detrusor overactivity can cause urgency and urinary incontinence in multiple sclerosis and spinal cord injury despite oral antimuscarinic therapy. In this prospective double-blind multicentre trial, patients with persistent urinary incontinence were randomized to intradetrusor onabotulinumtoxinA or placebo. Active treatment reduced the frequency of daily urinary incontinence and improved validated quality-of-life measures during the primary follow-up period. The study provides strong evidence for botulinum toxin as a local therapy when oral medication does not adequately control neurogenic bladder symptoms. The clinical trade-off is the risk of urinary retention, which may necessitate intermittent catheterisation. For HCPs, the practical pathway is therefore to assess bladder-emptying function before treatment and counsel patients about catheterisation if necessary. The intervention should form part of a broader neuro-urological assessment rather than being used solely to suppress urgency. The findings are directly relevant to IANCON's neuro-urology workshop, which addresses assessment and management of neurogenic bladder and sexual dysfunction in neurological patients.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
